AT Acrivon Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Follow the Acrivon Therapeutics, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €94.3m. The latest transaction was filed on 27 August 2026 (Cession). Among the most active insiders: Blume-Jensen Peter. All data is openly available.
Analyst consensus: bullish or bearish? Analysts rate Acrivon Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$11.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
All Executives118 Thresholds0 Prospectus0 Other0
Declarations 118 total
▼ President and CEO · Executives · 25 Aug 2026
14,036 shares @ US$2.2064 Common Stock SEC:0000905148-26-003968:0
● Officer, Director · Executives · 25 Aug 2026
14,036 shares @ US$2.18 0.032% mcap 100.0% of flow Common Stock SEC144:0000905148-26-003924
▼ President and CEO · Executives · 18 Aug 2026
1,229 shares @ US$2.01 0.0024% mcap 0.1% of flow Common Stock SEC:0000905148-26-003836:0
▼ President and CEO · Executives · 18 Aug 2026
484 shares @ US$2.01 0.0010% mcap 0.0% of flow Common Stock SEC:0000905148-26-003836:1
▼ Chief Development Officer · Executives · 18 Aug 2026
400 shares @ US$2.01 0.0008% mcap 3.1% of flow Common Stock SEC:0000905148-26-003838:0
▼ Chief Legal Officer · Executives · 18 Aug 2026
185 shares @ US$2.01 0.0004% mcap 0.6% of flow Common Stock SEC:0000905148-26-003839:0
▼ Chief Accounting Officer · Executives · 18 Aug 2026
101 shares @ US$2.01 0.0002% mcap 5.0% of flow Common Stock SEC:0000905148-26-003840:0
▼ Chief Operating Officer · Executives · 18 Aug 2026
604 shares @ US$2.01 0.0012% mcap 1.5% of flow Common Stock SEC:0000905148-26-003837:0
▼ Chief Financial Officer · Executives · 4 Aug 2026
1,142 shares @ US$1.57 0.0018% mcap 9.9% of flow Common Stock SEC:0000905148-26-003499:0
▼ Chief Legal Officer · Executives · 21 Jul 2026
573 shares @ US$1.76 0.0010% mcap 1.8% of flow Common Stock SEC:0000905148-26-003334:0
● President and CEO · Executives · 21 May 2026
13,729 shares @ US$1.79 0.5% of flow Common Stock SEC:0000905148-26-002652:0
◆ Director · Executives · 22 Apr 2026
3,888,888 shares @ US$1.80 6.82% mcap 17.6% of flow Common Stock SEC:0001231919-26-000396:0
● Chief Legal Officer · Executives · 17 Apr 2026
558 shares @ US$1.78 1.9% of flow Common Stock SEC:0000905148-26-001768:0
● President and CEO · Executives · 21 Feb 2026
14,265 shares @ US$1.53 0.5% of flow Common Stock SEC:0000905148-26-001010:0
● Chief Accounting Officer · Executives · 14 Feb 2026
116 shares @ US$1.63 4.8% of flow Common Stock SEC:0000905148-26-000939:0
● Chief Legal Officer · Executives · 14 Feb 2026
217 shares @ US$1.63 0.6% of flow Common Stock SEC:0000905148-26-000937:0
● Chief Development Officer · Executives · 14 Feb 2026
471 shares @ US$1.63 3.0% of flow Common Stock SEC:0000905148-26-000936:0
● Chief Operating Officer · Executives · 14 Feb 2026
723 shares @ US$1.63 1.5% of flow Common Stock SEC:0000905148-26-000935:0
● President and CEO · Executives · 14 Feb 2026
1,302 shares @ US$1.63 0.0% of flow Common Stock SEC:0000905148-26-000934:0
● Chief Legal Officer · Executives · 17 Jan 2026
659 shares @ US$1.98 2.3% of flow Common Stock SEC:0000905148-26-000281:0
▲ President and CEO · Executives · 14 Jan 2026
49,000 shares @ US$1.676 1.7% of flow Common Stock SEC:0000905148-26-000226:0
Canonical exit: 14 Apr 2026 (T+90) ▲ Chief Financial Officer · Executives · 14 Jan 2026
8,832 shares @ US$1.6983 90.9% of flow Common Stock SEC:0000905148-26-000225:0
Canonical exit: 14 Apr 2026 (T+90) ▲ Chief Operating Officer · Executives · 13 Jan 2026
10,000 shares @ US$1.7218 21.8% of flow Common Stock SEC:0000905148-26-000212:0
Canonical exit: 13 Apr 2026 (T+90) ● President and CEO · Executives · 21 Nov 2025
19,904 shares @ US$2.30 1.0% of flow Common Stock SEC:0000905148-25-004179:0
● President and CEO · Executives · 14 Nov 2025
59,765 shares @ US$2.24 2.9% of flow Common Stock SEC:0000905148-25-004127:0
25 of 118 declarations
Load more (93 remaining) 关于 Acrivon Therapeutics, Inc. Acrivon Therapeutics, Inc. 是一家生物制药公司，专注于开发癌症治疗的靶向疗法。该公司利用生物标志物平台来识别可能从其治疗中受益的患者。